# Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain

> **NCT01001715** · PHASE2 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 41 (actual)

## Conditions studied

- Back Pain

## Interventions

- **DRUG:** REGN475/SAR164877
- **DRUG:** Placebo (for REGN475/SAR164877)

## Key facts

- **NCT ID:** NCT01001715
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Business decision due to low subject recruitment and enrollment
- **Last updated:** 2013-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01001715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01001715, "Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01001715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*